Back to Search
Start Over
Análise de custo por desfecho das novas terapias de combinação tripla com lenalidomida para o mieloma múltiplo recidivado/refratário no Brasil.
- Source :
- JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde; Dec2020, Vol. 12 Issue 3, p189-194, 6p
- Publication Year :
- 2020
-
Abstract
- <i>Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
- Subjects :
- COST estimates
MULTIPLE myeloma
UNCERTAINTY
DRUG prices
PROGRESSION-free survival
Subjects
Details
- Language :
- Portuguese
- ISSN :
- 21752095
- Volume :
- 12
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde
- Publication Type :
- Academic Journal
- Accession number :
- 147762298
- Full Text :
- https://doi.org/10.21115/JBES.v12.n3.p189-94